VJHemOnc is committed to improving our service to you

ASH 2019 | bb21217: next gen anti-BCMA CAR-T for R/R MM

VJHemOnc is committed to improving our service to you

Jesús Berdeja

Jesus Berdeja, MD, Director of Myeloma Research, Sarah Cannon Research Institute, Nashville, TN, gives an update on the results from an ongoing phase I clinical study (CRB-402; NCT03274219) of bb21217, a next-generation anti-BCMA CAR T-cell therapy, in heavily pretreated relapsed/refractory multiple myeloma (MM). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter